Flupirtine as Oral Treatment in Multiple Sclerosis

PHASE2TerminatedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
DRUG

Flupirtine

300 mg daily (divided in two doses)

DRUG

Placebo

twice daily

Trial Locations (4)

10117

NeuroCure Clinical Research Center, Charité Berlin, Berlin

37075

University of Göttingen, Department of Neurology, Göttingen

03048

Carl-Thiem-Clinic Cottbus, Cottbus

Unknown

University of Ulm, Department of Neurology, Ulm

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

Charite University, Berlin, Germany

OTHER